Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Multiple Ascending Dose and DDI Study
- Conditions
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 62
- Registration Number
- NCT03031119
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
- Conditions
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Chiayi Christian Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT03024684
- Locations
- 🇨🇳
Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan
🇨🇳E-DA Hospital, Kaohsiung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT03018444
- Locations
- 🇩🇰
University Hospital, Gentofte, Copenhagen, Hellerup, Region Hovedstaden, Denmark
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Gloria Vega
- Target Recruit Count
- 3
- Registration Number
- NCT03004001
- Locations
- 🇺🇸
DallasVAMC, Dallas, Texas, United States
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT02984982
- Locations
- 🇯🇵
Investigational Site Number 392008, Gifu-shi, Japan
🇯🇵Investigational Site Number 392022, Chiyoda-ku, Japan
🇯🇵Investigational Site Number 392039, Hiroshima-shi, Japan
Statin Immune Study
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 18
- Registration Number
- NCT02984293
- Locations
- 🇬🇧
University of Dundee, Dundee, United Kingdom
A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2016-12-02
- Target Recruit Count
- 90
- Registration Number
- NCT02979704
- Locations
- 🇧🇩
BSMMU, Dhaka, Bangladesh
Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Lady Davis Institute
- Target Recruit Count
- 60
- Registration Number
- NCT02967653
- Locations
- 🇨🇦
McGill University Health Centre, Montréal, Quebec, Canada
🇨🇦Douglas Mental Health University Institute, Montréal, Quebec, Canada
🇨🇦Jewish General Hospital, Montréal, Quebec, Canada
The Effect on EPCs by Statin Loading in "All Comers" With an ACS
- Conditions
- Interventions
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University Hospitals of North Midlands NHS Trust
- Target Recruit Count
- 40
- Registration Number
- NCT02957162
- Locations
- 🇬🇧
University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, United Kingdom
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02943590
- Locations
- 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸University of Pennsylvania Medical System, Philadelphia, Pennsylvania, United States
🇨🇦McGill University Health Center, Toronto, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.